FDA Warns About Musculoskeletal Pain With Bisphosphonate Use
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency asks physicians to consider discontinuing treatment despite lack of causal link to pain.
You may also be interested in...
FDA Evaluates Potential Link Between Bisphosphonate Class And Atrial Fibrillation
Recent journal articles on the osteoporosis products’ association with atrial fibrillation spark an “early safety communication" from the agency.
NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
New Look At Ezetimibe Fails To Confirm Vytorin Cancer Signal
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: